Emily Cork
Acute Care · Huntsville, ALNPI 1245620236
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 322 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 16.8% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,517, more than ten times the $238 reported in 2021. Among acute care clinicians in AL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 322 payments — averaging $21.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- Insmed, Inc.$661
- AstraZeneca$654
- Sanofi$635
- Takeda Pharmaceuticals U.S.A., Inc.$533
- Regeneron Healthcare Solutions, Inc.$526
- plus $3K from 25 others
What the payments were for
- Food & beverage$6,773100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 73 | $1,138 |
| Insmed, Inc. | 28 | $661 |
| AstraZeneca | 27 | $654 |
| Sanofi | 24 | $635 |
| Takeda Pharmaceuticals U.S.A., Inc. | 26 | $533 |
| Regeneron Healthcare Solutions, Inc. | 22 | $526 |
| Boehringer Ingelheim | 19 | $431 |
| Grifols USA, LLC | 14 | $335 |
| Harmony Biosciences LLC | 12 | $303 |
| Mylan Specialty L.p. | 11 | $249 |
| Jazz Pharmaceuticals Inc. | 7 | $164 |
| Genentech USA, Inc. | 8 | $142 |
| Axsome Therapeutics, Inc. | 6 | $139 |
| Avadel CNS Pharmaceuticals, LLC | 7 | $123 |
| Viatris Specialty LLC | 4 | $101 |
| Merck | 5 | $78 |
| Actelion Pharmaceuticals US, Inc. | 3 | $70 |
| Pfizer | 4 | $66 |
| Inspire Medical Systems, Inc. | 2 | $59 |
| Philips North America LLC | 3 | $57 |
| Vifor Pharma, Inc. | 2 | $48 |
| Pulmonx Corporation | 2 | $48 |
| Amgen | 2 | $41 |
| Inogen, Inc. | 3 | $37 |
| United Therapeutics Corporation | 2 | $30 |
| Astellas Pharma US Inc | 1 | $20 |
| Melinta Therapeutics, LLC | 1 | $19 |
| Optinose US, Inc. | 1 | $19 |
| Gilead | 1 | $18 |
| Lilly USA, LLC | 1 | $17 |
| Resmed Corp | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BREZTRI$124
How this compares
$6,773 in reported general payments places this provider in the 90th percentile of 711 acute care providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 20 | $341,380 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 289 | $229,279 |
| Breo ElliptaFluticasone/Vilanterol | 289 | $141,535 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 134 | $92,842 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 134 | $63,209 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 102 | $55,920 |
| Spiriva RespimatTiotropium Bromide | 77 | $47,941 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 60 | $41,481 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 71 | $24,474 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 843 | $23,367 |
| Spiriva HandihalerTiotropium Bromide | 33 | $23,344 |
| SymbicortBudesonide/Formoterol Fumarate | 65 | $22,795 |
| DuleraMometasone/Formoterol | 30 | $11,945 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 58 | $11,458 |
| Arnuity ElliptaFluticasone Furoate | 32 | $9,204 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat, Combivent Respimat | $431 | $494,011291 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta, Incruse Ellipta | $1,138 | $443,867734 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $654 | $122,926211 claims |
| MerckDulera | $78 | $11,94530 claims |
| PfizerEliquis | $66 | $8,18212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 711 acute care providers in Alabama.
Other acute care in Huntsville
- April KlarHuntsville$13K
- Stephanie TateHuntsville$13K
- Kelly VazquezHuntsville$12K
- Summer SlaterHuntsville$12K
- Tiffany RentzHuntsville$11K
- Britanie MooreHuntsville$9K
- Trey WilsonHuntsville$8K
- Esther HambrickHuntsville$8K
- Jessica BurkeenHuntsville$8K
- Alyssa EzellHuntsville$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.